Diabetes Therapeutics and Research Center, Institute for Genome Research, The University of Tokushima, Tokushima, Japan.
Clin Endocrinol (Oxf). 2012 Jan;76(1):78-87. doi: 10.1111/j.1365-2265.2011.04165.x.
To date, approximately 35 different POU1F1 mutations have been described in patients with familial and sporadic combined pituitary hormone deficiency (CPHD) from different ethnic backgrounds. The majority are missense mutations clustered within the conserved POU-specific and POU-homeo domains, encoded by exons 4 and 6, respectively.
This study aimed to identify the molecular basis and clinical characteristics of a Japanese CPHD family with a novel POU1F1 mutation.
The POU1F1 gene was sequenced in identical twin brothers with mild CPHD. The mutation identified was also evaluated in family members as well as 188 Japanese controls and then examined in functional studies.
A novel heterozygous splice site mutation (Ex2 + 1G>T; c.214 + 1G>T) was detected. This mutation was also present in their undiagnosed mother, but not in any of the controls. In vitro splicing studies suggested this mutation to result in an in-frame skipping of exon 2, thus producing an internally deleted protein lacking most of the R2 transactivation subdomain (TAD-R2). Heterologous expression studies of the mutated POU1F1 protein showed only modest reductions in its transactivation activities in HEK293T cells, while acting as a dominant-negative inhibitor of the endogenous activities of POU1F1 in pituitary GH3 cells.
This is the first report of a mutation at the exon 2 donor splice site of POU1F1, affecting TAD-R2. The addition of this mutation to the growing list of pathological POU1F1 mutations may provide deeper insights into clinical heterogeneity in the expressions of individual mutations and a better understanding of the structure-function relationships of POU1F1.
迄今为止,已经在来自不同种族背景的家族性和散发性联合垂体激素缺乏症(CPHD)患者中描述了大约 35 种不同的 POu1F1 突变。大多数是错义突变,聚集在保守的 POu 特异性和 POu-homeo 结构域内,分别由外显子 4 和 6 编码。
本研究旨在鉴定一个具有新型 POu1F1 突变的日本 CPHD 家族的分子基础和临床特征。
对患有轻度 CPHD 的同卵双胞胎兄弟进行 POu1F1 基因测序。鉴定出的突变也在家族成员以及 188 名日本对照中进行了评估,然后在功能研究中进行了检查。
检测到一种新型的异源剪接位点突变(Ex2 + 1G>T;c.214 + 1G>T)。该突变也存在于他们未确诊的母亲中,但不存在于任何对照中。体外剪接研究表明,该突变导致外显子 2 内框跳跃,从而产生缺失大部分 R2 反式激活子亚域(TAD-R2)的内部缺失蛋白。突变 POu1F1 蛋白的异源表达研究表明,其在 HEK293T 细胞中的反式激活活性仅略有降低,而在垂体 GH3 细胞中作为 POu1F1 内源性活性的显性负抑制剂。
这是 POu1F1 外显子 2 供体位点突变影响 TAD-R2 的首次报道。将该突变添加到不断增加的病理性 POu1F1 突变列表中,可能会更深入地了解个体突变表达的临床异质性,并更好地了解 POu1F1 的结构-功能关系。